MODERNA : to start their final stage clinical trials of its vaccine against COVID-19
Vaccine candidate – mRNA-1273
A clinical stage biotechnology company pioneering mRNA therapeutics and vaccines to create a new generation of transformative medicine for patients, announced progress on late-stage development of mRNA-1273.
With the phase-III dose being finalized at 100μg, the company remains on track to be able to deliver approximately 500 million doses per year.
About mRNA-1273 »
It is an mRNA vaccine against COVID-19 encoding for a perfusion stabilized form of the Spike(S) protein.
First clinical batch (Phase-I) – March 16,2020
By SUBHAM SINGHA (Science & Tech Division)
IGNITED MINDS
Click here to follow us on YouTube
Click here to follow us on Facebook
Comments
Post a Comment